<DOC>
	<DOCNO>NCT00536484</DOCNO>
	<brief_summary>This Phase 3B study design test fesoterodine flexible dose regimen effective placebo reduce micturition frequency overactive bladder ( OAB ) symptom , e.g. , urgency , urgency incontinence episode patient overactive bladder fesoterodine regimen safe well tolerate .</brief_summary>
	<brief_title>Fesoterodine Flexible Dose Study</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Overactive bladder symptom great equal 3 month . Mean urinary frequency great equal 8 micturition per 24 hour bladder diary . Mean number Urgency episodes great equal 3 per 24 hour bladder diary . Contraindication fesoterodine ( antimuscarinics ) . Known etiology OAB ( e.g. , neurogenic , local urinary tract pathology ) . Previous history acute urinary retention require catheterization severe void difficulty judgment investigator , prior baseline . Unable follow study procedure , include completion selfadministered bladder diary patient report outcome questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>